Thymosin ß4 and MRTF-A mitigate vessel regression despite cardiovascular risk factors

Christian Kupatt, Tilman Ziegler, Andrea Bähr, Ferdinand Le Noble

Publikation: Beitrag in FachzeitschriftArtikelBegutachtung

Abstract

Since clinical revascularization techniques of coronary or peripheral artery disease (CAD/PAD) focus on macrovessels of the heart, the microcirculatory compartment largely goes unnoticed. However, cardiovascular risk factors not only drive large vessel atherosclerosis, but also microcirculatory rarefaction, an instance unmet by current therapeutic schemes. Angiogenic gene therapy has the potential to reverse capillary rarefaction, but only if the disease-causing inflammation and vessel-destabilization are addressed. This review summarizes the current knowledge with regard to capillary rarefaction due to cardiovascular risk factors. Moreover, the potential of Thymosin ß4 (Tß4) and its downstream signal, myocardin-related transcription factor-A (MRTF-A), to counteract capillary rarefaction are discussed.

OriginalspracheEnglisch
Aufsatznummer109786
FachzeitschriftInternational Immunopharmacology
Jahrgang117
DOIs
PublikationsstatusVeröffentlicht - Apr. 2023
Extern publiziertJa

Fingerprint

Untersuchen Sie die Forschungsthemen von „Thymosin ß4 and MRTF-A mitigate vessel regression despite cardiovascular risk factors“. Zusammen bilden sie einen einzigartigen Fingerprint.

Dieses zitieren